Business Context and Reporting Period
This Form 8-K is filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on June 16, 2022. The report addresses a regulatory notice regarding the company's continued listing status on The Nasdaq Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price deficiency triggering the notice.
Material Changes
- Listing Non-Compliance: The company received notice from Nasdaq that its common stock failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive trading days.
- Compliance Period: The company has been granted an initial 180-day compliance period to regain compliance, ending on December 13, 2022.
Outlook, Risks, and Management Commentary
- Remediation Plan: To regain compliance, the closing bid price must be at least $1.00 per share for 10 consecutive trading days before the deadline.
- Extension Option: If compliance is not met by the initial deadline, the company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market and meets specific market value standards.
- Risk of Delisting: Failure to regain compliance within the granted periods will result in the delisting of the common stock.
- Management Stance: The company intends to monitor the stock price and consider available options to resolve the noncompliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current closing bid price of Graybug Vision, Inc. (ticker: GRAY) to assess progress toward the $1.00 threshold.
- Monitor future filings for any announcements regarding a reverse stock split or transfer to The Nasdaq Capital Market.
- Confirm the company's market value of publicly held shares if a transfer to the Capital Market is pursued.
- Check for any subsequent 8-K filings indicating a failure to meet the December 13, 2022, deadline.